Business
REGENXBIO Announces Presentations at the 18th Annual WORLDSymposium™ 2022
ROCKVILLE, Md., Jan. 31, 2022 /PRNewswire/ -- Interim data from Phase I/II trials of RGX-121 for the treatment of MPS II and RGX-111 for the treatment of MPS
About this update from Regenxbio Inc.
[{"type":"text","content":"ROCKVILLE, Md., Jan. 31, 2022 /PRNewswire/ -- \nInterim data from Phase I/II trials of RGX-121 for the treatment of MPS II and RGX-111 for the treatment of MPS I to be presentedREGENXBIO Inc. (Nasdaq: RGNX) today announced that five oral and seven poster presentations will be presented at the 18th Annual WORLDSymposium™, taking place in San Diego, CA from February 7 through 11, 2022. The presentations include interim results from the Phase I/II clinical trials of RGX-121 for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter Syndrome, and RGX-111 for the treatment of mucopolysaccharidosis type I (MPS I), also known as Hurler Syndrome.\nThe oral presentations will be presented as follows:\nAbstract Title: Treatment of cardiac, neurologic, and skeletal manifestations of murine MPS I with AAV9-IDUA: Efficacy study of vector dose and route of administrationPresenter: Lalitha Belur, Ph.D., Research Assistant Professor Genetics, Cell Biology and Development at University of MinnesotaDate/Time: Tuesday, February 8, 2022, 12:12 p.m. ET\nAbstract Title: RGX-121 gene therapy for the treatment of severe mucopolysaccharidosis type II (MPS II): Interim analysis of data from the first in-human studyPresenter: Roberto Giugliani, M.D., Ph.D., Professor, Department of Genetics, UFRGS, Medical Genetics Service, HCPA, Porto Alegre, BrazilDate/Time: Wednesday, February 9, 2022, 11:12 a.m. ET\nAbstract Title: RGX-111 gene therapy for the treatment of severe mucopolysaccharidosis type I (MPS I): Interim analysis of data from the first in-human studyPresenter: Raymond Wang, M.D., Division of Metabolic Disorders, CHOC Children's Hospital, Department of Pediatrics, University of California, Irvine, CADate/Time: Wednesday, February 9, 2022, 11:36 a.m. ET\nAbstract Title: Identification of a biomarker that differentiates neuronopathic forms of MPS I and MPS IIPresenter: Nidal Boulos, Ph.D., Director, Clinical Scientist at REGENXBIO Inc.Date/Time: Thursday, February 10, 2022, 11:24 a.m. ET\nAbstract Title: Establishment of in vitro model of CLN2 retinopathy using human induced pluripotent stem cellsPresenter: Kwi Hye Kim, Ph.D., Senior Scientist, Preclinical Development at REGENXBIO Inc.Date/Time: Friday, February 11, 2022, 1:40 p.m. ET\nThe poster presentations will be presented as follows:\nAbstract Title: Safety, Pharmacodynam...